Symbols / CANF
CANF Chart
About
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.75M |
| Enterprise Value | -560.42K | Income | -8.80M | Sales | 560.00K |
| Book/sh | 3.16 | Cash/sh | 4.88 | Dividend Yield | — |
| Payout | 0.00% | Employees | 5 | IPO | — |
| P/E | inf | Forward P/E | -6.01 | PEG | — |
| P/S | 10.26 | P/B | 1.39 | P/C | — |
| EV/EBITDA | 0.06 | EV/Sales | -1.00 | Quick Ratio | 3.04 |
| Current Ratio | 3.60 | Debt/Eq | 2.15 | LT Debt/Eq | — |
| EPS (ttm) | 0.00 | EPS next Y | -0.73 | EPS Growth | — |
| Revenue Growth | -36.10% | Earnings | 2025-08-28 08:00 | ROA | -81.86% |
| ROE | -264.12% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -24.25% | Profit Margin | 0.00% | Shs Outstand | 1.31M |
| Shs Float | 1.32M | Short Float | 5.77% | Short Ratio | 0.75 |
| Short Interest | — | 52W High | 46.60 | 52W Low | 3.40 |
| Beta | -0.50 | Avg Volume | 227.80K | Volume | 8.90K |
| Target Price | $50.00 | Recom | None | Prev Close | $4.56 |
| Price | $4.39 | Change | -3.73% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$50.00
Mean price target
2. Current target
$4.39
Latest analyst target
3. DCF / Fair value
$-70.02
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.39
Low
$50.00
High
$50.00
Mean
$50.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-17 | main | D. Boral Capital | Buy → Buy | $4 |
| 2025-11-18 | main | D. Boral Capital | Buy → Buy | $11 |
| 2025-09-16 | main | D. Boral Capital | Buy → Buy | $11 |
| 2025-09-02 | main | D. Boral Capital | Buy → Buy | $11 |
| 2025-07-29 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-04-15 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-21 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-20 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-18 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-03 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-02-18 | main | D. Boral Capital | Buy → Buy | $10 |
| 2024-12-31 | main | D. Boral Capital | Buy → Buy | $10 |
| 2024-12-05 | main | D. Boral Capital | Buy → Buy | $10 |
| 2024-11-12 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-07-17 | init | EF Hutton | — → Buy | $10 |
| 2024-05-09 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2023-10-24 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2023-06-02 | reit | HC Wainwright & Co. | — → Buy | $34 |
| 2023-03-13 | reit | HC Wainwright & Co. | — → Buy | $34 |
- Experimental obesity pill namodenoson trims weight gain in high-fat diet study - Stock Titan ue, 17 Feb 2026 12
- Can-Fite BioPharma Announces Special Shareholder Meeting for Capital Restructuring - The Globe and Mail Sat, 04 Oct 2025 07
- CANF: Analyst Jason Kolbert Maintains Buy Rating and Price Targe - GuruFocus ue, 18 Nov 2025 08
- Can Fite Biopharma surges on pre-market trading - Intellectia AI hu, 05 Feb 2026 13
- Can Fite Biopharma stock tumbles after announcing 1-for-3,000 reverse split - Investing.com ue, 23 Dec 2025 08
- Obesity pill Namodenoson wins Canada patent nod after 2.3% weight loss data - Stock Titan Mon, 09 Feb 2026 08
- Can-Fite Announces Up To $15.0 Million Public Offering - Yahoo Finance Mon, 28 Jul 2025 07
- Loss Report: Is CANF stock good for income investors - Sell Signal & Reliable Intraday Trade Alerts - baoquankhu1.vn Sat, 21 Feb 2026 23
- Can-Fite Achieves 9-Year Survival Milestone in Liver Cancer Treatment - TipRanks ue, 18 Nov 2025 08
- symbol__ Stock Quote Price and Forecast - CNN ue, 21 Nov 2023 13
- CANF: D. Boral Capital Lowers Price Target But Maintains Buy Rat - GuruFocus Wed, 17 Dec 2025 08
- Brazil grants patent for a new way to tackle sexual dysfunction - Stock Titan Fri, 26 Dec 2025 08
- Can-Fite BioPharma Discloses Resignation of Director Yaacov Goldman - The Globe and Mail Sat, 17 Jan 2026 08
- H.C. Wainwright assumes coverage on Can-Fite BioPharma stock with Buy rating - Investing.com ue, 04 Nov 2025 08
- Buy Signal: Is CANF stock good for income investors - Weekly Gains Report & Safe Capital Investment Plans - baoquankhu1.vn Sun, 22 Feb 2026 03
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -8.10M | -8.25M | -9.80M | -13.05M |
| TotalUnusualItems | -27.00K | 69.00K | -283.00K | 221.00K |
| TotalUnusualItemsExcludingGoodwill | -27.00K | 69.00K | -283.00K | 221.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.88M | -7.63M | -10.17M | -12.62M |
| ReconciledDepreciation | 7.00K | 15.00K | 14.00K | 14.00K |
| EBITDA | -8.12M | -8.18M | -10.08M | -12.83M |
| EBIT | -8.13M | -8.20M | -10.10M | -12.84M |
| NetInterestIncome | 277.00K | 492.00K | 206.00K | 6.00K |
| InterestIncome | 291.00K | 506.00K | 222.00K | 24.00K |
| NormalizedIncome | -7.85M | -7.70M | -9.89M | -12.84M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.88M | -7.63M | -10.17M | -12.62M |
| TotalExpenses | 8.80M | 8.94M | 10.91M | 13.70M |
| TotalOperatingIncomeAsReported | -8.13M | -8.20M | -10.10M | -12.84M |
| DilutedAverageShares | 7.25M | 4.26M | 2.72M | 1.84M |
| BasicAverageShares | 7.25M | 4.26M | 2.72M | 1.84M |
| DilutedEPS | 0.00 | -3.00 | -3.00 | -9.00 |
| BasicEPS | 0.00 | -3.00 | -3.00 | -9.00 |
| DilutedNIAvailtoComStockholders | -7.88M | -7.63M | -10.17M | -15.21M |
| NetIncomeCommonStockholders | -7.88M | -7.63M | -10.17M | -15.21M |
| OtherunderPreferredStockDividend | 0.00 | 0.00 | 2.59M | |
| NetIncome | -7.88M | -7.63M | -10.17M | -12.62M |
| NetIncomeIncludingNoncontrollingInterests | -7.88M | -7.63M | -10.17M | -12.62M |
| NetIncomeContinuousOperations | -7.88M | -7.63M | -10.17M | -12.62M |
| TaxProvision | 0.00 | 0.00 | 0.00 | |
| PretaxIncome | -7.88M | -7.63M | -10.17M | -12.62M |
| OtherIncomeExpense | -27.00K | 69.00K | -283.00K | 221.00K |
| GainOnSaleOfSecurity | -27.00K | 69.00K | -283.00K | 221.00K |
| NetNonOperatingInterestIncomeExpense | 277.00K | 492.00K | 206.00K | 6.00K |
| TotalOtherFinanceCost | 14.00K | 14.00K | 16.00K | 18.00K |
| InterestIncomeNonOperating | 291.00K | 506.00K | 222.00K | 24.00K |
| OperatingIncome | -8.13M | -8.20M | -10.10M | -12.84M |
| OperatingExpense | 8.80M | 8.94M | 10.91M | 13.70M |
| ResearchAndDevelopment | 5.76M | 5.98M | 7.76M | 9.85M |
| SellingGeneralAndAdministration | 3.05M | 2.96M | 3.14M | 3.85M |
| GeneralAndAdministrativeExpense | 3.05M | 2.96M | 3.14M | 3.85M |
| OtherGandA | 3.05M | 2.96M | 3.14M | 3.85M |
| TotalRevenue | 674.00K | 743.00K | 810.00K | 853.00K |
| OperatingRevenue | 674.00K | 743.00K | 810.00K | 853.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 2.98B | 1.36B | 815.75M | 815.75M |
| ShareIssued | 2.98B | 1.36B | 815.75M | 815.75M |
| TotalDebt | 104.00K | 40.00K | 62.00K | 124.00K |
| TangibleBookValue | 5.44M | 6.24M | 4.47M | 14.38M |
| InvestedCapital | 5.44M | 6.24M | 4.47M | 14.38M |
| WorkingCapital | 6.93M | 7.89M | 6.66M | 17.34M |
| NetTangibleAssets | 5.44M | 6.24M | 4.47M | 14.38M |
| CapitalLeaseObligations | 104.00K | 40.00K | 62.00K | 124.00K |
| CommonStockEquity | 5.44M | 6.24M | 4.47M | 14.38M |
| TotalCapitalization | 5.44M | 6.24M | 4.47M | 14.38M |
| TotalEquityGrossMinorityInterest | 5.44M | 6.24M | 4.47M | 14.38M |
| StockholdersEquity | 5.44M | 6.24M | 4.47M | 14.38M |
| GainsLossesNotAffectingRetainedEarnings | 1.13M | 1.13M | 1.13M | 1.13M |
| OtherEquityAdjustments | 1.13M | 1.13M | 1.13M | 1.13M |
| RetainedEarnings | -166.36M | -158.48M | -150.85M | -140.67M |
| AdditionalPaidInCapital | 170.67M | 163.60M | 154.19M | 153.93M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 3.68M | 3.75M | 4.81M | 5.87M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.63M | 1.73M | 2.31M | 3.14M |
| NonCurrentDeferredLiabilities | 1.58M | 1.71M | 2.29M | 3.07M |
| NonCurrentDeferredRevenue | 1.58M | 1.71M | 2.29M | 3.07M |
| LongTermDebtAndCapitalLeaseObligation | 51.00K | 13.00K | 14.00K | 71.00K |
| LongTermCapitalLeaseObligation | 51.00K | 13.00K | 14.00K | 71.00K |
| CurrentLiabilities | 2.05M | 2.02M | 2.50M | 2.73M |
| CurrentDeferredLiabilities | 405.00K | 622.00K | 783.00K | 818.00K |
| CurrentDeferredRevenue | 405.00K | 622.00K | 783.00K | 818.00K |
| CurrentDebtAndCapitalLeaseObligation | 53.00K | 27.00K | 48.00K | 53.00K |
| CurrentCapitalLeaseObligation | 53.00K | 27.00K | 48.00K | 53.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 675.00K | 694.00K | 492.00K | 603.00K |
| PayablesAndAccruedExpenses | 919.00K | 677.00K | 1.18M | 1.26M |
| CurrentAccruedExpenses | 301.00K | 250.00K | 283.00K | 302.00K |
| Payables | 618.00K | 427.00K | 896.00K | 954.00K |
| AccountsPayable | 618.00K | 427.00K | 896.00K | 954.00K |
| TotalAssets | 9.12M | 9.99M | 9.28M | 20.25M |
| TotalNonCurrentAssets | 138.00K | 81.00K | 126.00K | 185.00K |
| NetPPE | 138.00K | 81.00K | 126.00K | 185.00K |
| AccumulatedDepreciation | -52.00K | -263.00K | -248.00K | -234.00K |
| GrossPPE | 190.00K | 344.00K | 374.00K | 419.00K |
| Leases | 0.00 | 13.00K | 13.00K | 13.00K |
| OtherProperties | 64.00K | 62.00K | 62.00K | 62.00K |
| MachineryFurnitureEquipment | 126.00K | 269.00K | 299.00K | 344.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 8.98M | 9.91M | 9.16M | 20.07M |
| OtherCurrentAssets | 1.09M | 986.00K | 1.17M | 929.00K |
| PrepaidAssets | 908.00K | 1.12M | 881.00K | |
| Receivables | 47.00K | 48.00K | ||
| OtherReceivables | 47.00K | 48.00K | ||
| CashCashEquivalentsAndShortTermInvestments | 7.89M | 8.92M | 7.99M | 19.14M |
| OtherShortTermInvestments | 3.06M | 4.64M | 5.01M | 14.75M |
| CashAndCashEquivalents | 4.83M | 4.28M | 2.98M | 4.39M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -7.64M | -8.44M | -10.81M | -9.87M |
| IssuanceOfCapitalStock | 6.71M | 9.14M | 0.00 | 20.46M |
| CapitalExpenditure | -5.00K | -2.00K | -9.00K | -11.00K |
| InterestPaidSupplementalData | 0.00 | 0.00 | 18.00K | |
| EndCashPosition | 4.83M | 4.28M | 2.98M | 4.39M |
| BeginningCashPosition | 4.28M | 2.98M | 4.39M | 8.27M |
| EffectOfExchangeRateChanges | -22.00K | 98.00K | -113.00K | 34.00K |
| ChangesInCash | 569.00K | 1.20M | -1.30M | -3.91M |
| FinancingCashFlow | 6.71M | 9.14M | 0.00 | 20.46M |
| CashFlowFromContinuingFinancingActivities | 6.71M | 9.14M | 0.00 | 20.46M |
| NetCommonStockIssuance | 6.71M | 9.14M | 0.00 | 20.46M |
| CommonStockIssuance | 6.71M | 9.14M | 0.00 | 20.46M |
| InvestingCashFlow | 1.50M | 498.00K | 9.50M | -14.51M |
| CashFlowFromContinuingInvestingActivities | 1.50M | 498.00K | 9.50M | -14.51M |
| NetInvestmentPurchaseAndSale | 1.50M | 500.00K | 9.51M | -14.50M |
| PurchaseOfInvestment | -14.50M | |||
| NetPPEPurchaseAndSale | -5.00K | -2.00K | -9.00K | -11.00K |
| PurchaseOfPPE | -5.00K | -2.00K | -9.00K | -11.00K |
| OperatingCashFlow | -7.64M | -8.44M | -10.80M | -9.86M |
| CashFlowFromContinuingOperatingActivities | -7.64M | -8.44M | -10.80M | -9.86M |
| ChangeInWorkingCapital | -267.00K | -943.00K | -1.30M | 2.43M |
| ChangeInOtherWorkingCapital | -349.00K | -743.00K | -810.00K | 1.40M |
| ChangeInOtherCurrentLiabilities | -32.00K | -84.00K | -62.00K | -63.00K |
| ChangeInOtherCurrentAssets | 55.00K | |||
| ChangeInPayablesAndAccruedExpense | 223.00K | -300.00K | -188.00K | 967.00K |
| ChangeInPayable | 223.00K | -300.00K | -188.00K | 967.00K |
| ChangeInAccountPayable | 191.00K | -469.00K | -58.00K | 393.00K |
| ChangeInPrepaidAssets | -109.00K | 184.00K | -241.00K | 128.00K |
| OtherNonCashItems | 90.00K | -222.00K | 113.00K | -46.00K |
| StockBasedCompensation | 362.00K | 261.00K | 263.00K | 466.00K |
| UnrealizedGainLossOnInvestmentSecurities | 14.00K | -11.00K | 229.00K | -162.00K |
| AssetImpairmentCharge | 37.00K | 94.00K | 54.00K | 55.00K |
| DepreciationAmortizationDepletion | 7.00K | 15.00K | 14.00K | 14.00K |
| DepreciationAndAmortization | 7.00K | 15.00K | 14.00K | 14.00K |
| Depreciation | 7.00K | 15.00K | 14.00K | 14.00K |
| OperatingGainsLosses | 68.00K | |||
| NetForeignCurrencyExchangeGainLoss | 68.00K | |||
| NetIncomeFromContinuingOperations | -7.88M | -7.63M | -10.17M | -12.62M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for CANF
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|